Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Metastatic NSCLC Patients With PDX
NCT03134456Phase 4Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2018
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Started May 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03134456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03134456.